Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery.

Article Details

Citation
Copy to clipboard

Dohil R, Cabrera BL, Gangoiti JA, Barshop BA, Rioux P

Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery.

Fundam Clin Pharmacol. 2014 Apr;28(2):136-43. doi: 10.1111/fcp.12009. Epub 2012 Oct 31.

PubMed ID
23113697 [ View in PubMed
]
Abstract

Cysteamine is approved for the treatment of cystinosis and is being evaluated for Huntington's disease and non-alcoholic fatty liver disease. Little is known about the bioavailability and biodistribution of the drug. The aim was to determine plasma, cerebrospinal fluid (CSF), and tissue (liver, kidney, muscle) cysteamine levels following intraduodenal delivery of the drug in rats pretreated and naive to cysteamine and to estimate the hepatic first-pass effect on cysteamine. Healthy male rats (n = 66) underwent intraduodenal and portal (PV) or jugular (JVC) venous catheterization. Half were pretreated with cysteamine, and half were naive. Following intraduodenal cysteamine (20 mg/kg), serial blood samples were collected from the PV or the JVC. Animals were sacrificed at specific time points, and CSF and tissue were collected. Cysteamine levels were determined in plasma, CSF, and tissue. The Cmax was achieved in 5-10 min from PV and 5-22.5 min from JVC. The PV-Cmax (P = 0.08), PV-AUC0-t (P = 0.16), JVC-Cmax (P = 0.02) and JVC-AUC0-t (P = 0.03) were higher in naive than in pretreated animals. Plasma cysteamine levels returned to baseline in

DrugBank Data that Cites this Article

Drugs